FDA Reprimands Gilead Over Letairis Statements

Law360 (March 9, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration has chastised Gilead Sciences Inc. for a sales representative's “false and misleading” statements that misbranded the hypertension drug Letairis and minimized “serious risks” associated with the medication.

In a letter to Gilead posted Thursday to its Web site, the FDA targeted statements made by the unnamed sales representative at a June 2008 international pulmonary hypertension conference in Houston.

Among other things, the agency said the representative stated that a risk management plan for Letairis issued by the FDA was “not...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.